Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Isis is a biopharmaceutical company focused on RNA-based drug discovery, primarily utilizing antisense technology to inhibit disease-causing proteins. The company operates through three main divisions: Antisense Drug Discovery/Development, GeneTrove (functional genomics services), and Ibis Therapeutics (infectious disease diagnostics and small molecule drugs). Isis has one approved product, Vitravene (for CMV retinitis), and a pipeline of 12 antisense products in various stages of clinical development.
Key Financial Metrics
| Metric (in thousands) | 2002 | 2001 |
|---|---|---|
| Total Revenue | $80,179 | $53,273 |
| Research & Development Expenses | $124,074 | $83,741 |
| Net Loss | $(72,242) | $(73,832) |
| Net Loss Applicable to Common Stock | $(73,302) | $(75,131) |
| Cash, Cash Equivalents & Short-Term Investments | $289,353 | $312,018 |
| Working Capital | $244,230 | $280,569 |
| Long-Term Debt & Capital Leases | $192,893 | $125,710 |
| Accumulated Deficit | $(459,893) | $(386,591) |
Liquidity: Management believes available cash, cash equivalents, and short-term investments, combined with investment income and committed contractual payments, are sufficient to meet anticipated requirements for at least the next 36 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $26.9 million (50%) to $80.2 million, driven primarily by increased research and development revenue under collaborative agreements, specifically the strategic alliance with Eli Lilly and Company.
- Expense Increase: Operating expenses rose by $31.6 million to $131.0 million. Research and development expenses increased by $40.4 million due to expanded clinical trials (including three Phase III trials) and costs associated with Lilly and Amgen collaborations.
- Debt Restructuring: In May 2002, the company issued $125 million of 5.5% convertible subordinated notes. Proceeds were used to prepay $74 million of 14% Senior Subordinated Notes (resulting in a $2.3 million loss) and $19.7 million of 12% convertible debt held by Elan (resulting in a $5.0 million gain).
- Joint Venture Exits: Elan concluded its participation in the HepaSense (Hepatitis C) and Orasense (oral formulation) joint ventures in late 2002. Isis regained full rights to the underlying drug candidates (ISIS 14803 and ISIS 104838).
- Restructuring: The company terminated its GeneTrove database product offering in November 2002, resulting in a workforce reduction of approximately 25 people and a one-time restructuring charge of $1.4 million.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Affinitak (Lung Cancer): Results from a Phase III trial showed no difference in overall survival (primary endpoint) compared to chemotherapy alone. However, secondary analyses suggested activity. The company and Lilly are performing in-depth analysis and will decide on future development based on ongoing trials.
- Alicaforsen (Crohn's Disease): Two Phase III trials are ongoing in North America and Europe. Enrollment is expected to complete by early 2004.
- Manufacturing: Construction of a new manufacturing suite dedicated to Affinitak was completed in February 2003, funded by a $21 million loan from Lilly.
Risks and Contingencies
- Clinical Trial Failure: The company faces significant risk if drug candidates fail to demonstrate safety or efficacy in clinical trials, as evidenced by the Affinitak Phase III results.
- Regulatory Approval: Failure to obtain FDA or foreign regulatory approval for any product would prevent commercialization.
- Partner Dependence: The business relies heavily on collaborative partners (e.g., Lilly, Amgen) for funding and commercialization. Withdrawal of partner support could delay or stop development.
- Profitability: The company has incurred losses since inception (accumulated deficit of ~$460 million) and expects to incur additional operating losses in the near future.
- Manufacturing Scale-Up: The company has limited experience in large-scale commercial manufacturing of oligonucleotides, which poses a risk to future product supply.
Key Facts for Investor Verification
- Affinitak Trial Data: Verify the final analysis of the Phase III Affinitak trial data and the decision timeline with Lilly regarding further development.
- Cash Burn Rate: Confirm the company's ability to fund operations for the projected 36-month runway given the high R&D spend and lack of product sales revenue (Vitravene sales are limited).
- Debt Obligations: Review the terms of the $125 million convertible notes and the $100 million interest-free loan from Lilly, including conversion prices and repayment conditions.
- Joint Venture Transitions: Assess the impact of regaining full rights to ISIS 14803 and ISIS 104838 from Elan on future development costs and timelines.
- GeneTrove Revenue: Monitor the revenue contribution from GeneTrove collaborations following the termination of the database product and workforce reduction.